RegeneRx receives notice of allowance for key dry eye patent in U.S.
RegeneRx Biopharmaceuticals announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Thymosin beta 4 for use in the treatment of dry eye syndrome. TB4 is the active pharmaceutical ingredient in RegeneRx's proprietary drug candidate, RGN-259, a first-in-class product candidate designed for topical administration to patients suffering from dry eye syndrome. RegeneRx's second Phase 3 dry eye trial, ARISE-2, is being sponsored by the company's U.S. joint venture, ReGenTree LLC, and was completed in July in approximately 600 dry eye patients in an effort to reproduce the clinically significant results seen in ARISE-1. Patient data are expected to be released by the fourth quarter of 2017.